J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner
J&J’s 5-year acquaintanceship with OSE Immunotherapeutics has come to an end as the pharma giant decided it doesn’t want the CD28 antagonist FR104 after all.
The deal termination means that Nantes, France-based OSE will once again hold worldwide rights to the asset — including any new data, IP and regulatory filings generated by J&J’s biotech unit Janssen — which is now ready for Phase II testing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.